Search

Displaying results 6591 - 6600 of 6949 in total
  1. Drug

    Dextofisopam

    go.drugbank.com/drugs/DB06582
    Investigational

  2. Drug

    Pegargiminase

    go.drugbank.com/drugs/DB06592
    Investigational

    Pegargiminase is an anticancer agent.

  3. Drug

    Ciluprevir

    go.drugbank.com/drugs/DB05868
    Investigational

    The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.

  4. Drug

    Anamorelin

    go.drugbank.com/drugs/DB06645
    Investigational

  5. Drug

    Huperzine B

    go.drugbank.com/drugs/DB03348
    Experimental

    Huperzine B is a novel acetylcholinesterase inhibitor.

  6. Drug

    Ranpirnase

    go.drugbank.com/drugs/DB04950
    Investigational

    Ranpirnase is a ribonuclease enzyme found in Rana pipiens oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.

  7. Drug

    Bectumomab

    go.drugbank.com/drugs/DB04962
    Experimental

    Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.

  8. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of t...

  9. Drug

    Besifovir dipivoxil

    go.drugbank.com/drugs/DB05020
    Investigational

    Besifovir dipivoxil is a small-molecule orally available inhibitor of the HBV polymerase. The HBV polymerase is the enzyme that catalyzes the production of new RNA from the existing strand of RNA. Besifovir dipivoxil is believed to inhib...

  10. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effe...